Latest news with #HoneywellSolsticeAir
Time of India
22-05-2025
- Health
- Time of India
Lupin introduces Honeywell Solstice Air inhalers for sustainable respiratory care
Representative image (Picture credit: X/@LupinGlobal) BENGALURU: Lupin is using Honeywell's Solstice Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%. ' By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact,' said Vinita Gupta, CEO Lupin. 'Solstice Air can play a critical role in ensuring that Lupin's respiratory inhalers provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,' said Ashish Modi, President of Honeywell India. 'By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions-reducing practices that support industry advancements. ' Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Business Standard
20-05-2025
- Health
- Business Standard
Lupin to develop next-gen inhalers using Honeywell's Solstice Air propellant
Lupin announced today its plan to use Honeywell's Solstice Air (HFO-1234ze cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Lupin intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.1 By investigating the use of this innovative, non flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD. L
